Anthem Biosciences Ltd

Anthem Biosciences Ltd has announced the closure of its trading window for all designated persons. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the board meeting where financial results for the quarter ending June 30, 2026, are approved. The company is adhering to SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct. Designated persons have been duly informed not to engage in any trading of the company's securities during this period. The exact date of the board meeting will be communicated to the stock exchanges in due course.

Aruna Ganesh, a member of the Promoter Group of Anthem Biosciences Limited, has sold her entire shareholding of 1,71,14,604 equity shares, representing 3.05% of the paid-up equity share capital. The transaction, which occurred on June 18, 2026, was conducted via the open market. Despite this sale, Aruna Ganesh's status as a member of the Promoter Group remains unchanged. The disclosure was made in accordance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Anthem Biosciences Ltd announced its audited consolidated financial results for FY26 and Q4FY26. FY26 revenue from operations reached ₹21,243 Mn, with EBITDA at ₹9,896 Mn (43.4% margin) and PAT at ₹5,918 Mn (26.0% margin). Q4FY26 revenue stood at ₹6,109 Mn, with EBITDA at ₹3,184 Mn (48.1% margin) and PAT at ₹1,898 Mn (28.7% margin). The company reported a net cash position of ₹13,743 Mn as of March 31, 2026.

Anthem Biosciences Ltd reports key performance indicators for the financial year 2025-26. Total revenue from operations reached ₹21,243.33 million, with a year-on-year growth of 15.17%. Revenue from Contract Research, Developmental & Commercial Manufacturing (CRDMO) stood at ₹17,727.68 million, while revenue from Specialty Ingredients (SI) was ₹3,515.65 million. The ratio of revenue from operations from CRDMO: SI was 83:17. EBITDA was ₹8,971.69 million with a margin of 47.07%, and PAT was ₹5,917.92 million with a margin of 25.95%.

Anthem Biosciences Ltd's Board of Directors approved several key items at its meeting on May 19, 2026. These include audited financial results for the year ended March 31, 2026, a final dividend of ₹2.00 per share, convening the 20th Annual General Meeting on July 22, 2026, and the allotment of 14,81,250 equity shares under the ESOP 2024. The board also approved the re-appointment of M/s. BPU & Co. as Internal Auditor and recommended the continuation of Mr. Ravikant Uppal and the re-appointment of Mr. Ravindra Chandrappa as Directors, subject to shareholder approval.

Anthem Biosciences Ltd announced its audited consolidated financial results for FY26 and Q4FY26. FY26 revenue from operations reached ₹21,243 Mn, with an EBITDA of ₹9,896 Mn (43.4% margin) and a PAT of ₹5,918 Mn (26.0% margin). Q4FY26 revenue stood at ₹6,109 Mn, with an EBITDA of ₹3,184 Mn (48.1% margin) and a PAT of ₹1,898 Mn (28.7% margin). The company reported a net cash position of ₹13,743 Mn as of March 31, 2026.

Anthem Biosciences Ltd's board meeting on May 19, 2026, approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹2.00 per equity share. The board also approved the allotment of 14,81,250 equity shares under the Anthem Employee Stock Option Plan 2024, increasing the paid-up equity share capital. The 20th Annual General Meeting is scheduled for July 22, 2026. The board approved the re-appointment of internal auditors and recommended the continuation and re-appointment of certain directors, subject to shareholder approval.

Anthem Biosciences Ltd's board has recommended a final dividend of ₹2.00 per equity share for FY26, subject to shareholder approval at the AGM. The record date for dividend payment is set for June 26, 2026. The board also approved the audited financial results for FY26, the 20th AGM on July 22, 2026, allotment of equity shares under ESOP 2024, re-appointment of internal auditors, and continuation/re-appointment of directors.

Anthem Biosciences Ltd's Board approved standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹2.00 per equity share, subject to shareholder approval. The 20th Annual General Meeting will be held on July 22, 2026. The board also approved the allotment of 14,81,250 equity shares under the Anthem Employee Stock Option Plan 2024 and re-appointed M/s. BPU & Co. as Internal Auditors. They recommended the continuation of Mr. Ravikant Uppal as Non-Executive Independent Director and the re-appointment of Mr. Ravindra Chandrappa as Whole Time Director, both subject to shareholder approval.

Anthem Biosciences Ltd's board approved standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹2.00 per equity share, subject to shareholder approval. The board also approved the allotment of 14,81,250 equity shares under the ESOP plan, re-appointment of internal auditors, and continuation/re-appointment of directors, subject to shareholder approval.